GlassScriptPhysician profile
Matthew Bell
NPI 1558921981
$1,394.30
in general payments reported to CMS, 2019-2025
21 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $315 · 2024: $700 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,299 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,299.31 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $215.26 | 2023-2025 | |
| Astellas Pharma US INC | $202.61 | 2023-2025 | Veozah |
| Mallinckrodt Hospital Products INC. | $146.16 | 2024 | Terlivaz |
| Lilly USA, LLC | $120.59 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $89.84 | 2023-2024 | Farxiga, Breztri |
| Dexcom, INC. | $89.51 | 2023-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $88.00 | 2023-2025 | Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $75.53 | 2024-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $54.40 | 2025 | |
| Abbott Laboratories | $53.22 | 2024-2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $46.92 | 2023-2024 | Quviviq |
| Sumitomo Pharma America, INC. | $36.49 | 2023-2024 | Gemtesa |
| Amgen INC. | $24.55 | 2023 | Repatha |
| Axsome Therapeutics, INC. | $23.75 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.15 | 2024 | Xifaxan |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $21.28 | 2023 | Nexplanon |
| Sanofi-Aventis U.S. LLC | $20.36 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.60 | 2024 | Jardiance |
| Dynavax Technologies Corporation | $15.31 | 2025 | Heplisav-B |
| Exact Sciences Corporation | $14.44 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $14.33 | 2025 | Bexsero, Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.